Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | HBB | P68871 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL628770 | 0.85 | LMNA (0.39) | LMNASLC6A6CYP2C19BLMALDH1A1 | |
| SCHEMBL3480921 | 0.83 | LMNA (0.50) | LMNASLC6A6CYP2C19BLMALDH1A1 | |
| SCHEMBL11195053 | 0.83 | LMNA (0.38) | LMNASLC6A6CYP2C19BLMALDH1A1 | |
| SCHEMBL1810867 | 0.83 | LMNA (0.33) | LMNASLC6A6CYP2C19BLM | |
| SCHEMBL1727488 | 0.81 | LMNA (0.42) | LMNASLC6A6CYP2C19BLMALDH1A1 | |
| SCHEMBL5070482 | 0.81 | LMNA (0.32) | LMNASLC6A6CYP2C19BLM | |
| SCHEMBL1067729 | 0.81 | LMNA (0.32) | LMNASLC6A6CYP2C19BLM | |
| SCHEMBL28769326 | 0.79 | CA2 (0.45) | ALDH1A1TSHR | |
| SCHEMBL355846 | 0.78 | — | — | |
| SCHEMBL3667694 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3429611-B1 | POLYCOMPLEXES OF POLY-LYSINE COMPOUNDS FOR PREVENTING AND/OR COMBATTING AMYOTROPHIC LATERAL SCLEROSIS | PLL THERAPEUTICS (FR) | 2023-06-07 | — | — | EP | claimed |
| WO-2024058984-A2 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MarvelBiome, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-3429611-B1 | POLYCOMPLEXES OF POLY-LYSINE COMPOUNDS FOR PREVENTING AND/OR COMBATTING AMYOTROPHIC LATERAL SCLEROSIS | PLL THERAPEUTICS (FR) | 2023-06-07 | — | — | EP | disclosed |
| US-10927342-B2 | Taurine supplemented cell culture medium and methods of use | Regeneran Pharmaceuticals, Inc. (US) | 2021-02-23 | — | — | US | disclosed |
| EP-3694646-A1 | A STREAMLINED METHOD FOR ANALYTICAL VALIDATION OF BIOCHEMICALS DETECTED USING AN UNTARGETED MASS-SPECTROMETRY PLATFORM | Metabolon, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20200157492-A1 | TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2020-05-21 | — | — | US | disclosed |
| WO-2020067386-A1 | MILD-COGNITIVE-IMPAIRMENT EVALUATION METHOD, CALCULATION METHOD, EVALUATION DEVICE, CALCULATION DEVICE, EVALUATION PROGRAM, CALCULATION PROGRAM, RECORDING MEDIUM, EVALUATION SYSTEM, AND TERMINAL DEVICE | 味の素株式会社 | 2020-04-02 | — | — | WO | disclosed |
| WO-2020011235-A1 | SKIN MOISTURE RETENTION COMPOSITION AND SKIN BEAUTY METHOD THEREFOR | 久文股份有限公司 | 2020-01-16 | — | — | WO | disclosed |
| CN-110483342-A | A kind of method and removal of impurities recovery system of taurine mother liquor removal of impurities recycling | QIANJIANG YONGAN PHARMACEUTICAL CO LTD | 2019-11-22 | — | — | CN | disclosed |
| US-20190214145-A1 | Method and systems for creating and screening patient metabolite profile to diagnose current medical condition, diagnose current treatment state and recommend new treatment regimen | KUREK ITZHAK (US) | 2019-07-11 | — | — | US | disclosed |
| WO-2005027950-A1 | EYE NUTRITIONAL SUPPLEMENT | RAY AND TERRY'S HEALTH PRODUCTS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1517681-A1 | PERITONEAL DIALYSATE CONTAINING TAURINE | JMS Co., Ltd. (JP) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004002467-A1 | PERITONEAL DIALYSATE CONTAINING TAURINE | JMS CO., LTD. (JP) | 2004-01-08 | — | — | WO | disclosed |
| EP-1158972-A4 | TREATMENT OF HYPERTENSION WITH COMPOUNDS THAT INHIBIT THE DESTRUCTION OF ENKEPHALINS OR ENDORPHINS | EHRENPREIS SEYMOUR (US) | 2003-05-02 | — | — | EP | disclosed |
| WO-2003033020-A1 | COMPOSITION AND METHOD TO TREAT POST-ILLNESS WASTING PHENOMENON | GANADO RESEARCH, L.L.C. (US) | 2003-04-24 | — | — | WO | disclosed |
| EP-1158972-A1 | TREATMENT OF HYPERTENSION WITH COMPOUNDS THAT INHIBIT THE DESTRUCTION OF ENKEPHALINS OR ENDORPHINS | Ehrenpreis, Seymour (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6207190-B1 | SYNERGISTIC MIXTURE TO REDUCE OCULAR PRESSURE AND IMPROVE VASCULAR HEALTH COMPRISING FOLIC ACID, A MAGNESIUM SALT, ALPHA-TOCOPHEROL, ASCORBATE AND ALPHA-LIPOIC ACID | CHRONORX, LLC | 2001-03-27 | — | — | US | disclosed |
| WO-2000041686-A1 | TREATMENT OF HYPERTENSION WITH COMPOUNDS THAT INHIBIT THE DESTRUCTION OF ENKEPHALINS OR ENDORPHINS | EHRENPREIS SEYMOUR (US) | 2000-07-20 | — | — | WO | disclosed |
| US-5539024-A | REACTION PRODUCT OF PERFLUOROALKYL SULFONAMIDE, OXYETHYLENE COMPOUND SUCH AS POLYETHERESTER, AND EPOXY COMPOUND SUCH AS NOVOLAC GLYCIDYL ETHER, PROTECTIVE COATINGS FOR PAPER, TEXTILES, LEATHER, MINERALS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-07-23 | — | — | US | disclosed |
| WO-1994027151-A1 | UTILIZATION OF MOLECULES RECOGNIZED BY AUTO-ANTIBODIES OF HUMAN SERUMS FOR THE DIAGNOSIS OR TREATMENT OF AIDS | GEFFARD MICHEL (FR) | 1994-11-24 | — | — | WO | disclosed |